Mitsui Chemicals Inc
Mitsui Chemicals is a Japan-based materials and chemicals company serving mobility, healthcare, agriculture, electronics, packaging and other markets. Its products include petrochemicals, basic chemicals, polyurethane inputs, elastomers, plastics and specialty materials. The company also supplies ophthalmic and medical materials, personal care and agricultural products, semiconductor and battery materials, imaging and packaging solutions, and genetic testing and analysis services. It operates in Japan and international markets.
No enriched coverage for $MITUF in the last 7 days.
No SEC Form 4 filings for $MITUF in the last 30 days.
See all $MITUF insider activity →Deloitte launched Edisyl, an AI company formed from Flipside Crypto’s AI business acquisition, adding 24 employees. BlueMatrix completed its acquisition of Aiera, an AI financial research platform. Mitsui Chemicals agreed to acquire JSR for ¥1.84 trillion ($11.6 billion), strengthening its semiconductor materials position.
iORGANBIO, a life sciences startup, received a strategic investment from Mitsui Chemicals (TSE: 4183) and will collaborate to combine AI with high-oxygen-permeability cell culture plates. The partnership aims to address organoid reproducibility, a critical issue in drug testing, as the FDA ends animal testing requirements. iORGANBIO's CellForge™ platform uses AI and robotics to guide cell differentiation, while Mitsui's plates improve oxygen supply to 3D cell cultures.
Brookfield Asset Management plans to triple its real estate assets under management in Asia-Pacific, focusing on residential, commercial, and AI-related properties. The firm recently acquired Japanese real estate and aims to expand in India. According to the company, it is bullish on the region's growth prospects.
Recent MITUF coverage spans mergers & acquisitions, financial news and corporate actions.
Deloitte launched Edisyl, an AI company formed from Flipside Crypto’s AI business acquisition, adding 24 employees. BlueMatrix completed its acquisition of Aiera, an AI financial research platform. Mitsui Chemicals agreed to acquire JSR for ¥1.84 trillion ($11.6 billion), strengthening its semiconductor materials position.
iORGANBIO, a life sciences startup, received a strategic investment from Mitsui Chemicals (TSE: 4183) and will collaborate to combine AI with high-oxygen-permeability cell culture plates. The partnership aims to address organoid reproducibility, a critical issue in drug testing, as the FDA ends animal testing requirements. iORGANBIO's CellForge™ platform uses AI and robotics to guide cell differentiation, while Mitsui's plates improve oxygen supply to 3D cell cultures.
Brookfield Asset Management plans to triple its real estate assets under management in Asia-Pacific, focusing on residential, commercial, and AI-related properties. The firm recently acquired Japanese real estate and aims to expand in India. According to the company, it is bullish on the region's growth prospects.
Japan’s Mitsui Chemicals, DBJ to Buy JSR for $12 Billion, Bloomberg reports.
Mitsui Chemicals (4183) shares dropped 11.6% to ¥1,830 after a Reuters report stated that Japan Investment Corp plans to sell chipmaker JSR to the company for over ¥1.3 trillion ($8.2 billion). Investors are concerned about the financial strain and potential equity dilution or increased leverage. Analysts are divided on the long-term benefits of the deal, but the broader market also fell, with the Nikkei 225 down nearly 2%.
AlphAI scores every news story that mentions MITUF with an AI model for sentiment and relevance, and aggregates insider trades from Mitsui Chemicals Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Deloitte launched Edisyl, an AI company formed from Flipside Crypto’s AI business acquisition, adding 24 employees. BlueMatrix completed its acquisition of Aiera, an AI financial research platform. Mitsui Chemicals agreed to acquire JSR for ¥1.84 trillion ($11.6 billion), strengthening its semiconductor materials position.
iORGANBIO, a life sciences startup, received a strategic investment from Mitsui Chemicals (TSE: 4183) and will collaborate to combine AI with high-oxygen-permeability cell culture plates. The partnership aims to address organoid reproducibility, a critical issue in drug testing, as the FDA ends animal testing requirements. iORGANBIO's CellForge™ platform uses AI and robotics to guide cell differentiation, while Mitsui's plates improve oxygen supply to 3D cell cultures.
Brookfield Asset Management plans to triple its real estate assets under management in Asia-Pacific, focusing on residential, commercial, and AI-related properties. The firm recently acquired Japanese real estate and aims to expand in India. According to the company, it is bullish on the region's growth prospects.
Japan’s Mitsui Chemicals, DBJ to Buy JSR for $12 Billion, Bloomberg reports.
Mitsui Chemicals (4183) shares dropped 11.6% to ¥1,830 after a Reuters report stated that Japan Investment Corp plans to sell chipmaker JSR to the company for over ¥1.3 trillion ($8.2 billion). Investors are concerned about the financial strain and potential equity dilution or increased leverage. Analysts are divided on the long-term benefits of the deal, but the broader market also fell, with the Nikkei 225 down nearly 2%.
Japan Investment Corp plans to sell JSR, a chipmaking materials maker, to Mitsui Chemicals for around $8.2 billion, according to Reuters. The state-backed fund acquired JSR two years ago for 900 billion yen and is now selling due to higher valuations in the semiconductor sector.
Mitsui Chemicals, Inc. introduced InnoCell P-Type, a cell culture plate designed for 3D organoid models and drug discovery, with high oxygen permeability and low autofluorescence. The product aims to enhance drug screening processes. According to the company, it is an early-stage launch in the life sciences tooling sector.
Mitsui Chemicals said it completed its acquisition of U.S. oral care company Ultradent Products on Aug. 14, 2026, earlier than the expected September timeline, after competition and foreign investment approvals were obtained. It plans to move its oral care global HQ function from Japan to a U.S. holding company and will review the deal’s impact on consolidated financial results.
Ultradent Products agreed to be acquired by Mitsui Chemicals in a $900 million deal, with closing expected in September 2026, subject to regulatory approvals and filings. Mitsui Chemicals registered MC Dental Holdings America in Utah to oversee its global oral-care business, with headquarters in South Jordan. Ultradent reported 2025 sales of $372.1 million and net income of $24.0 million.
Mitsui Chemicals said it joined CuspAI’s AI Materials Foundry as a founding member, joining a 45+ member network that includes Nvidia, Meta, Samsung, Henkel, Applied Materials, Tokyo Electron and others. The network uses CuspAI’s MIRA platform to combine data, computing resources and facilities to speed AI-driven materials discovery. Mitsui aims to strengthen R&D and explore new business opportunities.
